Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Nalena vs Spry

Nalena
Graded #98

Higher grade

vs+14.400000000000006
Spry
Graded #409

Lower grade

The verdict

Nalena takes it — 71.2/100 to 56.8/100.

Nalena grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Nalena is a women-focused, GLP-1-only telehealth platform offering compounded semaglutide and tirzepatide with medication included — no separate membership or visit fees.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNalena +20
74
54
Dose & formulationEven
64
64
Clinical oversightNalena +27
82
55
Labs & monitoringNalena +1
53
52
FulfillmentNalena +28
89
61
Contract termsNalena +6
61
55
Nalena · left barSpry · right bar

The numbers

MetricNalenaSpry
WeighScore71.2/10056.8/100
GradeCC
Scorecard rank#98#409
Semaglutide$149/mo (starting dose, compounded)$199/mo (starting dose, compounded)
Tirzepatide$149/mo (starting dose, compounded)$299/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Nalena

Graded #98 · C

Strengths

  • Compounded GLP-1 from $149/mo with medication included — near the floor of the compounded market
  • Transparent fee model: no hidden fees, no membership, cancel anytime
  • Money-back guarantee — uncommon among compounded telehealths
  • Clinical provider disclosed: Beluga Health, P.A. in Houston, TX
  • Women-focused positioning

Where it loses points

  • Per-dose pricing not published — only the 'starting at $149' entry price
  • No LegitScript, HIPAA, or NABP badges on public pages
  • Compounding pharmacy partners not named (only 'multiple USA certified pharmacies')
  • Houston address looks like a virtual office rather than a clinical facility
  • No brand-name GLP-1s (Wegovy, Zepbound, Ozempic, Mounjaro) — compounded only
Spry

Graded #409 · C

Strengths

  • Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
  • Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
  • Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
  • No contracts or commitment required
  • LegitScript Certified with a public verification link

Where it loses points

  • Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
  • Intake reviewed by a nurse practitioner, not an MD
  • States served not disclosed publicly
  • Pharmacy partner not named, and 503A vs 503B designation not specified
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard